From Genomics to Treatment through Collaboration: Year in Review 2025
As the year 2025 comes to an end, we reflect on a series of achievements in ProTarget and conclude with a little surprise looking ahead.
2025 marked a highly significant year for the trial, with major scientific milestones, expanded treatment opportunities, and strengthened national and international collaborations. Together, these achievements further solidified ProTarget’s role as a cornerstone of precision oncology in Denmark and an important contributor to the European precision cancer medicine landscape.
Major Scientific Milestones
During 2025, we participated in several national and international conferences and shared clinical outcome data from our trial. One of the highlights of 2025 was the ESMO Congress in Berlin, where we presented outcome data from the first 301 patients treated in our trial. Furthermore, we had the pleasure of presenting results from our BRAF and HER2 cohorts at the MAP conference in Paris. These milestones represent years of nationwide collaboration across clinical sites, molecular diagnostics, and the Danish National Molecular Tumor Board.
The results presented demonstrate that a subgroup of patients with advanced, treatment-refractory cancer can derive meaningful clinical benefit from molecularly matched targeted therapies when used outside their current approved indications. These findings underscore the untapped potential of already approved targeted drugs and the value of comprehensive genomic profiling in late-line cancer care.
Continued Expansion of Treatment Arms
In 2025, we continued to expand our treatment portfolio. Most notably, patient slots for pemigatinib (Pemazyre®) were expanded for the second time, bringing the total number of available slots to 80. This expansion enables further investigation of the efficacy and safety of FGFR-targeted therapy in a tumor-agnostic setting beyond the drug’s current labelled indication.
National Collaboration and Investigator Engagement
Strengthening collaboration across Denmark remained a key priority in 2025. The ProTarget Investigator Meetings, held in Copenhagen or online, brought together investigators and study personnel from all participating sites. The meeting served as an important forum for sharing clinical experiences, discussing preliminary results, and aligning on protocol updates, including newly added targeted therapies. These activities highlight the strength of the Danish precision oncology infrastructure and the value of close collaboration between clinicians, molecular biologists, and researchers.
A Final Achievement to Celebrate
As a special highlight at the end of 2025, we are delighted to share that we have received funding from the Danish Cancer Society’s Knæk Cancer initiative for a new translational research project focused on long-read sequencing. This project aims to improve the identification of patients who may benefit from HER2-targeted therapies by enabling more precise and comprehensive detection and interpretation of complex genomic alterations.
This support represents an important step forward in integrating advanced genomic technologies into precision oncology and further strengthens our translational research efforts in ProTarget.
We would like to extend our sincere thanks to all patients and their families, as well as to investigators and study personnel, national and international collaborators, and supporters. Your commitment and trust make it possible to push the boundaries of precision oncology and create new treatment opportunities for patients in need.
Happy New Year!
The ProTarget Sponsor Team
